Introduction
Since the emergence of the HIV pandemic, a close association between HIV infection and the development of a selected group of cancers has been brought to light (Boshoff and Weiss, 2002) . Several mechanisms of pathogenesis have been reported; yet the reason why neoplasia, in particular non-Hodgkin's lymphomas (NHL), is more common in the HIV than in other forms of immunodepression is not completely understood (Gaidano et al., 1998; Knowles, 1999) . The failure of CD4-helper T cells to recognize clones of abnormal proliferating cells may be one reason (Dalgleish and O'Byrne, 2002) , while the roles of cytokines and tumor suppressor genes are other areas of active research (Clark et al., 2000; Mahieux et al., 2001) . Tat protein of HIV is also a likely candidate to contribute to tumor pathogenesis in HIV-infected patients (Ensoli et al., 1994; Altavilla et al., 1999; Fiorelli et al., 1999; Kundu et al., 1999) . Tat protein is an early nonstructural protein necessary for virus replication, which is secreted by infected cells and taken up by uninfected cells (Rubartelli et al., 1998) . Extensive evidence indicates that Tat is a cofactor in the development of AIDSrelated neoplasms and the protein has also been found to have an oncogenic role in vitro and in vivo (Kim et al., 1992; Corallini et al., 1993 Corallini et al., , 1996 Kundu et al., 1999) . However, the molecular mechanism of Tat-mediated tumorigenesis is not clear at present. There is experimental evidence suggesting a potential role of Tat-mediated chemotaxis and invasion in the pathogenesis of AIDS-related malignancies (Barillari and Ensoli, 2002) . Deregulation of cellular genes and functions by Tat can also cause abnormalities that may contribute to AIDS pathogenesis and to the development of AIDS-associated disorders (Kundu et al., 1997 (Kundu et al., , 1998 Kashanchi et al., 2000) . Extracellular Tat is able to regulate many cellular genes that are involved in cell signaling and translation and ultimately controls the host proliferation and differentiation signals (Chang et al., 1995; Li et al., 1995; Zauli et al., 1995; De La Fuente et al., 2002) . The molecular mechanism underlying Tat's pleiotropic activity may include the generation of functional heterodimers of Tat with cell cycle proteins . In particular, Tat protein of HIV has also recently been shown to interact physically with RB2/p130 tumor suppressor gene product (Lazzi et al., 2002) .
RB2/p130 tumor suppressor gene belongs to the retinoblastoma gene family together with pRb and p107 (Stiegler et al., 1998) . Many of the sequence similarities among these genes reside in a homologous functional domain known as the pocket region. This particular region mediates the interaction with E2F/DP members and viral oncoproteins. There are fundamental differences in the specific mechanisms of growth inhibition employed by the proteins (Claudio et al., 1994 ). An example can be seen in the T98G cell line, which is refractory to the effects of pRb and p107 but undergoes growth arrest caused by pRb2/p130. Additionally, when associated with certain viral oncoproteins, the phosphorylation status of the retinoblastoma family members varies from one family member to another. Besides mutations of the gene Claudio et al., 2000a, b) , interaction with viral oncoproteins is another important mechanism of inactivation of pRb2/ p130, as oncoviral disruption of E2F/DP complexes reinduces site-dependent transcription and cell cycle progression (Fattaey et al., 1993; De Luca et al., 1997) .
The aim of the present paper is to elucidate whether the physical interaction between Tat protein of HIV and pRb2/p130 is able to inactivate the oncosuppressive properties of the latter. The understanding of this basic information may be of significance for early molecular diagnosis, prognosis and the implementation of future therapeutic regimes, including the design of new therapeutic approaches.
Materials and methods

Plasmids
The pRb2/p130 coding vectors have been previously described (Lazzi et al., 2002) . pcDNA-3 Tat and GST-Tat were obtained from M Giacca (International Center Engineering in Biotechnology, Trieste, Italy). The artificial E2F promoter containing three consecutive E2F consensus binding sites linked to a luciferase reporter gene has been previously described (Claudio et al., 2001) .
Cell lines
The human 293 and T98G cell lines were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). Cells were cultured in DMEM supplemented with 10% FBS, 1% l-glutamine, and penicillin/streptomycin, with 5% CO 2 at 371C.
Colony-formation assay
For the colony-formation assay, T98G cells were transfected with 10 mg of each vector and selected with 600 mg/ml G-418 (Sigma), starting at 48 h from transfection, for 3 weeks. Colonies were then washed with PBS and stained with 1% methylene blue in 50% ethanol.
Immunoprecipitation and western blotting
Cells were harvested and lysed in EBC buffer (50 mm Tris-HCl pH.8. 0, NaCl 120 mm, 0.5% NP40 and fresh inhibitors). The extracts were immunoprecipitated with a polyclonal anti-Tat antibody (Immunodiagnostics, MA, USA). Western blotting (WB) was performed with both monoclonal anti-pRb2/p130 antibody (Transduction Laboratory, UK) at a dilution of 1 : 400 and polyclonal anti-pRb2/p130 (Rockland) at a dilution of 1 : 400.
Transfections
Cells were transfected with the calcium phosphate kit (Invitrogen, CA, USA), using 10 mg of each plasmid for RNA and protein extraction, and 2 mg for the luciferase assay. At 48 h from transfection, cells were harvested for RNA, protein extraction or for the luciferase assay.
Half-life measurement
After transfection with Tat, transfected and untransfected cells were treated with cycloheximide and dissolved in ethanol, at a concentration of 25 mg/ml, for times ranging between 0 and 96 h. As a negative control, cells treated with ethanol alone were used.
RNA extraction
RNA was extracted using the Trizol reagent (Invitrogen, CA, USA), following the manufacturer's instructions.
RT-PCR
RNA. (400 ng) was reverse transcribed for 1 h at 421C, using Avian Myeloblastosis Virus (AMV) (Promega, WI, USA) and RNAsin (Promega, WI, USA) as enzymes. The cDNA (1 ml) was amplified by real-time PCR using the apparatus supplied by Roche. The DNA master SYBR green 1 kit (Roche Diagnostics, Germany) was used according to the manufacturer's conditions. The oligonucleotides used for pRb2/p130 have been previously described (Cinti et al., 2000a and b) . G3PDH was used as a control gene and mRNA levels for pRb2/p130 were rationalized to those for G3PDH. Primer sequences for G3PDH have been previously described .
Recombinant Tat
The recombinant Tat HIV-1 IIIB (aa 1-86) from Dr J Raina was obtained through the EU Programme EVA/MRC Centralised Facility for AIDS Reagents, NIBSC, UK (Grant numbers QLK2-CT-1999-00609 and GP828102). The stock solution was diluted in saline citrate buffer as recommended, and aliquots were stored at À801C until use. The concentration of endotoxin was below 0.01 endotoxin unit (EU)/mg of protein. Extracellular Tat (50 ng/ml) was added to the medium culture of 293 cells for 48 h. 293 cells, grown in the absence of Tat, were used as a control.
Luciferase assay
For the luciferase assay, 2 mg of each plasmid was transfected. Cells were harvested 48 h from transfection and subjected to a luciferase assay. Reactions were normalized by using betagalactosidase. The luciferase assay was performed in triplicate, as previously described (De Falco et al., 2000) .
Results
Tat and pRb2/p130 interact in vivo through the pocket region of pRb2/p130
Previously we demonstrated that Tat and pRb2/p130 interact both in vitro and in vivo (Lazzi et al., 2002) . Here, we mapped the site of this interaction occurring in vivo in the 293 cell line. Briefly, 293 cells were transfected with expression vectors coding for Tat and pRb2/p130 mutants, lacking the amino-and carboxyl-terminal Physical interaction between pRb2/p130 and Tat G De Falco et al domains, respectively. At 48 h from transfection, cells were harvested and cell extracts were immunoprecipitated with an anti-Tat antibody, followed by WB with two different anti-pRb2/p130 antibodies, directed against either the amino-or the carboxyl-terminal domains, depending on the region to be identified. The results are shown in Figure 1 . In both cases, Tat and pRb2/p130 still interact, even though p130 was deleted. This suggests that the carboxyl-and the amino-terminal domains are not necessary for this interaction, which occurs through the pocket region of pRb2/p130.
Tat induces an increase in pRb2/p130 mRNA levels
We monitored the levels of mRNA for pRb2/p130, either in the presence or in the absence of Tat. 293 cells were transfected with an expression vector coding for Tat or with the empty vector. Cells were harvested 48 h from transfection and RNA was extracted. The mRNA was reverse transcribed and then amplified by a realtime PCR, using specific primers for RB2/p130. The results indicate that the transcription level for pRb2/ p130 increases dramatically in the presence of Tat (Figure 2 ).
Tat does not alter the phosphorylation status of pRb2/ p130
In order to assess whether Tat may influence pRb2/p130 phosphorylation status, 293 cells were grown in the presence of extracellular Tat for 48 h. Wild-type cells cultured in the absence of Tat were also used as a control. We compared the phosphorylation status of pRb2/p130 in both the cell lines by using an anti-pRb2/ p130 antibody in WB. The result shows that no difference is observed in terms of pRb2/p130 phosphorylation status (Figure 3 ). In addition, 293 cells were also transfected with an expression vector coding for Tat, then harvested and subjected to WB with anti-pRb2/ p130 antibody. The result obtained using this approach also confirms that no significant difference in terms of pRb2/p130 phosphorylation is observed (data not shown). Half-life of pRb2/p130 was also monitored both in the presence and absence of Tat, and in this case no differences were observed (data not shown).
Tat inhibits pRb2/p130 control on cell cycle
To evaluate whether Tat is able to inhibit the oncosuppressive effect of pRb2/p130, T98G cells were transfected with expression vectors coding for pRb2/ p130, for Tat, and for both vectors together. The empty vector was also transfected as a positive control. T98G cells were used because this cell line contains normal pRb/p105 and is resistant to the suppression effect of both pRb/p105 and p107. Cells were then selected with G-418 and cultured for approximately 3 weeks in order to allow resistant cells to form colonies. The result is shown in Figure 4 . Cells transfected with pRb2/p130 alone formed few colonies compared to the wild-type cells, containing the empty vector. In the presence of Tat, pRb2/p130 seems to lose its growth-suppressive properties, as demonstrated by the increase in the number of colonies formed (Figure 4 ), in comparison to cells transfected with pRb2/p130 alone. This result suggests that Tat binding to pRb2/p130 is not just a physical interaction, but may lead to the deregulation of cell cycle control activities mediated by pRb2/p130, as demonstrated by the loss of its growth-suppressive properties.
The interaction with Tat does not release E2F-4 from pRb2/p130
To evaluate whether the interaction between Tat and pRb2/p130 disrupts the E2F4/p130 complexes, an artificial E2F promoter containing three consecutive E2F consensus binding sites (Claudio et al., 2001) linked to the luciferase reporter gene was expressed in 293 cells in the presence of either pRb2/p130 or Tat, or both together. At 48 h from transfection, cells were harvested and processed for luciferase assay. The results are shown in Figure 5 and demonstrate that E2F-4 is not released from pRb2/p130 in the presence of Tat, as no significant variation in promoter activation is observed. This suggests that Tat does not compete with E2F-4 in binding to pRb2/p130.
Discussion
HIV Tat, a nonstructural protein essential for viral replication, is a potent transactivator of the HIV LTR (Gatignol et al., 2000) . Tat also transactivates several endogenous cellular genes, including cytokines, extracellular matrix proteins, and proto-oncogenes (Vene et al., 2000) . Besides its nuclear localization and function, Tat protein can also be released into the extracellular environment by HIV-infected cells (Rubartelli et al., 1998) . Exogenous Tat has been suggested to have a wide range of activities due to the interaction of specific Tat domains with cellular receptors and cellular genes (Ensoli et al., 1993; Frankel and Pabo, 1988) . Extracellular Tat activities seem to mediate the majority of Tat effects in vivo and are implicated in the pathogenesis of HIV-related diseases (Vene et al., 2000) . Transgenic approaches provided evidence that there is a correlation between Tat protein expression and the insurgence of a variety of AIDS-related neoplasms including Kaposi's sarcoma (KS) and NHLs (Vogel et al., 1988; Corallini et al., 1993; Kundu et al., 1999) . The expression of Tat protein in tissues of AIDS-related lymphomas in humans has recently been demonstrated (Lazzi et al., 2002) . Interestingly, the same tumors overexpressed pRb2/p130 tumor suppressor protein by immunohistochemistry (Lazzi et al., 2002) . The overexpression of pRb2/p130 in tumors with high proliferative activity such as AIDS-related lymphomas suggested that the oncosuppressive properties of pRb2/ p130 could be inactivated (Lazzi et al., 2002) . In addition, an interaction between pRb2/p130 and Tat proteins of HIV was also detected in living cells (Lazzi et al., 2002) . The aim of the present paper is to investigate the effect of such an interaction on the oncosuppressive properties of pRb2/p130. First, we mapped the interaction of Tat and pRb2/ p130 in vivo, demonstrating that it occurs through the pocket region of pRb2/p130. We also monitored the levels of mRNA for pRb2/p130, either in the presence or in the absence of Tat and found that in the presence of Figure 4 Tat inhibits the growth control exerted by pRb2/p130. T98G cells transfected with Tat and pRb2/p130, alone or in combination, were positively selected for resistance to G-418. The addition of Tat to the culture determines the loss of the growth control mediated by pRb2/p130. The number of colonies observed in the sample, which overexpress both Tat and pRb2/p130, was comparable to those of the negative control containing the empty vector Figure 5 Tat does not compete with E2F-4 in binding to pRb2/ p130. A luciferase assay was performed on samples transfected with Tat and pRb2/p130, alone or in combination. Cotransfection of pRb2/p130 and Tat did not result in an increase in the activation of a promoter responsive to E2F-4, suggesting that E2F-4 is not released in the presence of Tat alone Physical interaction between pRb2/p130 and Tat G De Falco et al Tat, the transcription level for pRb2/p130 increases dramatically. Furthermore, the results presented here show that no significant difference in terms of pRb2/ p130 phosphorylation status is observed in the presence or absence of Tat, suggesting that the protein is not stabilized in the presence of Tat. These observations are in line with the overexpression of pRb2/p130 observed by immunohistochemistry in AIDS-related lymphomas (Lazzi et al., 2002) , and suggest that pRb2/p130 overexpression may be due to an increased transcription/translation for pRb2/p130 stimulated by Tat, rather than to an altered turnover of the protein, which requires pRb2/p130 phosphorylation (Stiegler et al., 1998) .
Secondly, we evaluated whether the previously demonstrated interaction of Tat with pRb2/p130 may have consequences on the ability of pRb2/p130 to control cell proliferation. The results of the colony formation assay demonstrate that, in T98G cells, the presence of Tat determines the loss of growth inhibition of pRb2/p130. This result suggests that Tat binding to pRb2/p130 is not just a physical interaction, but leads to the deregulation of cell cycle control activities by pRb2/ p130 and the loss of its growth-suppressive properties.
Our next aim was to determine through which molecular mechanism Tat inactivates the pRb2/p130 oncosuppressive function. There is increasing evidence that the pleiotropic activities of Tat are cell cycle related Ambrosino et al., 2002) . Progression through the cell cycle requires an ordered array of biochemical interactions, illustrated by the cyclin-Cdk complexes and their Cdk-inhibitory regulators (Sherr and Roberts, 1999) . The regulation of basal and upstream activator transcription factors also plays an important role in the coordinated cascade of the cell cycle. For example, the activity of the cellular transcription factor E2F is tightly regulated by the Rb proteins (Stein et al., 1999) . However, each Rb protein has a different temporary profile of interaction with different E2F members. pRb/p105 preferentially binds to a subset of E2F members E2F-1, -2, and -3, whereas pRb2/p130 and p107 binds to E2F-4 and -5. In G0, E2F-4 and -5 are associated with pRb2/p130 in a transcriptionally inactive complex (Paggi et al., 1996) . Upon mitogenic stimulation, E2F-4 is released from pRb2/p130, accumulates in free form, and initiates a cascade of events leading to progression of the cell cycle (Paggi et al., 1996) . The interaction of Tat with pRb2/p130 could thus interfere with the binding with E2F-4. Our results, however, show that the presence of Tat alone is not sufficient for the release of E2F-4, since no significant variation in an E2F-responsive promoter activation is observed. A similar mechanism has been described for other oncoproteins. The SV 40 large T antigen in fact binds to pRb2/p130 and E2F-4, but the release of E2F-4 from this complex is an active process, which is ATPdependent and mediated by a chaperone (Sullivan et al., 2000) .
The data described here demonstrate that Tat and pRb2/p130 interact through the pocket region of pRb2/ p130, resulting in the inhibition of pRb2/p130 oncosuppressive properties and uncontrolled cell proliferation. Whether this can occur through an ATP-dependent chaperone model remains to be determined. In addition, the interaction of Tat and pRb2/p130 alone may not be sufficient for neoplastic transformation in vivo and other cofactors may be required. This is also consistent with the finding that Tat cannot induce cell growth unless cells are previously activated with inflammatory cytokines (Ensoli et al., 1990; Barillari et al., 1992; Albini et al., 1995; Fiorelli et al., 1999) . Further studies are necessary to elucidate completely the molecular mechanism underlying the Tat-pRb2/p130 interaction. Nevertheless, these results open a window on the role of pRb2/p130 in AIDS-related oncogenesis and suggest a re-evaluation of HIV itself as an oncogenic virus. This may result in the implementation of future therapeutic regimes and the design of new therapeutic approaches.
